all semaglutide drugs Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity The FDA approved a pill

Key Growth Drivers: Increasing global obesity and diabetes burden Superior clinical efficacy in weight management Expanding indications including cardiovascular disease, MASH, CKD, and sleep apnea Growing adoption of oral GLP-1 medications Significant investments from leading pharmaceutical companies AI-powered drug discovery and innovation Expanding healthcare reimbursement and patient access As pharmaceutical leaders continue investing billions into next-generation GLP-1 therapies, this market is expected to reshape the future of cardiometabolic healthcare through 2035

I look back at pictures like, What was I thinking

In short, it doesnt just give you a glow

What about special life events